Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice.

Luis Alberto García-Rodríguez Mari-Ann Wallander Leif Friberg Ana Ruigómez Cristina Rebordosa Irene D Bezemer Ron M C Herings Saad Shakir Alison Evans Miranda Davies Kiliana Suzart-Woischnik Pareen Vora Yanina Balabanova Montse Soriano Gabarró Gunnar Brobert

Published in: Expert opinion on drug safety (2020)

The European rivaroxaban epidemiological PASS is a comprehensive program of complementary studies generating evidence from patients treated in routine clinical practice that will expand our understanding of the risk-benefit profile of rivaroxaban.

Keyphrases

clinical practice
venous thromboembolism
atrial fibrillation
pulmonary embolism
quality improvement